Recent Progress in CDK4/6 Inhibitors and PROTACs

Hao Wang, Jianfei Ba,Yue Kang, Zeqiao Gong,Tingting Liang,Yahong Zhang,Jianguo Qi,Jianhong Wang

Molecules(2023)

引用 0|浏览3
暂无评分
摘要
Cell division in eukaryotes is a highly regulated process that is critical to the life of a cell. Dysregulated cell proliferation, often driven by anomalies in cell Cyclin-dependent kinase (CDK) activation, is a key pathological mechanism in cancer. Recently, selective CDK4/6 inhibitors have shown clinical success, particularly in treating advanced-stage estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. This review provides an in-depth analysis of the action mechanism and recent advancements in CDK4/6 inhibitors, categorizing them based on their structural characteristics and origins. Furthermore, it explores proteolysis targeting chimers (PROTACs) targeting CDK4/6. We hope that this review could be of benefit for further research on CDK4/6 inhibitors and PROTACs.
更多
查看译文
关键词
cancer,cell cycle,CDK4/6 inhibitors,PROTACs
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要